Autosomal recessive congenital ichthyosis (ARCI) is a group of inherited keratinization disorders that are characterized by abnormal epidermal keratinization. ARCI patients generally represent serious symptoms including collodion baby phenotype accompanied by dehydration, heat loss, electrolytic imbalance, and sepsis. ARCI shows high degree of clinical and genetic heterogeneity. To date, nine genes were shown to be responsible for ARCI phenotype. One of these genes, patatin-like phospholipase domain containing protein-1 (PNPLA1) was suggested to be involved in the synthesis of ω-Oacylceramides related to epidermal cornified lipid envelope organization. In addition to previously reported PNPLA1 mutations, we report two novel PNPLA1 mutations including one novel missense mutation c.335C>A (p.Ser112Tyr) and one novel deletion mutation c.733_735delTAC (p.Tyr245del) in Turkish ARCI patients from unrelated consanguineous families. We also report previously reported missense mutation c.514G>A (p.Asp172Asn) in Turkish ARCI patients. Novel PNPLA1 mutations were shown to be located in the catalytic patatin domain of PNPLA1 gene. Identification of novel mutations in PNPLA1 gene expands the mutational spectrum in the causative gene. Increase in the total number of cases has high diagnostic value in terms of genotype-phenotype correlation in ARCI patients.
Autosomal recessive congenital ichthyosis (ARCI) comprises a group of clinically and genetically heterogeneous Mendelian disorders of cornification (MEDOC) with a prevalence of less than 1/200.000. 1,2 ARCI is mainly characterized by abnormal scaling over the whole body due to the defects in epidermal keratinocyte differentiation and lipid metabolism. 3, 4 The molecular mechanisms of ARCI are related to functional defects in the major components of epidermal barrier including intercellular lipid barrier, the cornified cell envelope and keratin or filaggrin degradation products. 5 The symptoms of ARCI may vary from mild to lethal conditions including hydroelectrolytic imbalance, thermal instability, dehydration, collodion baby phenotype and infection. 2, 4 To date, nine different genes including TGM1 6, 7 , ABCA12 8 , ALOXE3 9 , ALOX12B 9-11 , CYP4F22 12 , LIPN 13 , NIPAL4 14 , CERS3 15, 16 , and PNPLA1 17 were found to be associated with ARCI.
Patatin-like phospholipase domain containing 1 (PNPLA1) gene (Gene ID 285848) is defined as one of the ARCI causing genes. 17 PNPLA1 gene contains eight exons at chromosome 6p21.31. The cloned cDNA sequence is 1,599 bp. (GenBank accession No. FJ457781) encoding a polypeptide with 532 amino acids. PNPLA1 protein has a patatin domain (residues in the N-terminal region with serine-aspartate catalytic dyad (S53-D172) and a proline-rich domain (residues 326-451) in the C-terminal region. 18 Mammalian patatin-like phospholipase domain containing protein family (PNPLA1-9) have critical roles in diverse aspects of signaling pathways and lipid metabolism involving triglyceride lipase, hydrolase, and transacetylase activities. 19, 20 It is reported that human PNPLA1 protein is predominantly expressed in the keratinocytes of epidermal granular layer and plays role in lipid metabolism associated with cutaneous barrier formation. 17 In addition, recent studies reported that PNPLA1 function in the synthesis of omega-O-acylceramides as a transacylase and affect epidermal cornified lipid envelope organization. [21] [22] [23] To date, 26 different PNPLA1 mutations have been reported associated with ARCI. 17, [24] [25] [26] [27] 30 In the present study, we report two novel mutations, including one missense mutation c.335C>A (p.Ser112Tyr) and one deletion mutation c.733_735delTAC (p.Tyr245del), and also one previously reported missense mutation c.514G>A (p.Asp172Asn) in PNPLA1 gene in seven ARCI patients from three consanguineous Turkish families.
Case Report
Seven patients from three consanguineous families were recruited (Fig. 1) . The diagnosis of all patients was made by of clinical findings and histopathological features of skin biopsies. All detailed clinical findings are summarized in Table I . This study was approved by the Ethics Committee of Hacettepe University and informed consent to participate was obtained from all patients and/or parents.
Genotype analysis of selected individuals from a cohort of three consanguineous families with ARCI was achieved using genome-wide linkage analysis and Sanger DNA sequencing methods. Affymetrix 250K SNP arrays were used in order to perform genome-wide analysis according to manufacturer's recommendations. VIGENOS Software (Hemosoft, Ankara) was used for homozygosity mapping. The affected individuals showed a homozygous haplotype in the 6p21 region comprising PNPLA1 gene. Both DNA strands from the probands were entirely sequenced for the eight exons and for the intron/exon boundaries of the PNPLA1 gene. Details of PCR procedure were previously In this family, two affected individuals had a homozygous missense mutation (c.514G>A) in exon 4 of the PNPLA1 gene, which resulted in a G to A transition in the cDNA at position 514 downstream of the start codon (Fig. 2a) . The mutation results in replacement of aspartate with asparagine at position 172 (p.Asp172Asn). The missense mutation p.Asp172Asn is localized at the site of serine-aspartate catalytic dyad (S53-D172) in the patatin domain. The mutations in PNPLA1 were modeled by using SWISS_MODEL (http://swissmodel.expasy.org) (Fig. 3) . The exchange of an acidic amino acid aspartate with a uncharged amino acid glutamine at the position 172 may potentially disturb catalytic activity of the patatin domain (Fig. 3a) .
Family 2:
Three affected patients (II:1, II:3, II:4), diagnosed at ages 8, 5 and 5 respectively, from a consanguineous family (Family II), born as collodion babies and they had mild to moderate erythema on the face. Their skin presented generalized fine small, white and light brown scales. In flexures, brown linear thick plaques were seen. Similar lesions were present on the dorsum of hand and feet. They had palmoplantar keratoderma, pruritus and nail abnormality including toenail dystrophy and distal onycholysis. They had squamous pityriasiform appearance on the scalp. All patients in the family had large-octagonal scales on the legs.
The three affected individuals were found to have a novel homozygous deletion mutation (c.733_735delTAC) in exon 5 of the PNPLA1 gene (Fig. 2b) . This mutation causes the deletion of the tyrosine residue at position 245 (p.Tyr245del). Deletion of a tyrosine amino acid may cause an alteration in the alpha helix structure that most probably alters PNPLA1 protein folding (Fig. 3b) . The pathogenicity of identified mutations was evaluated by using prediction programs PolyPhen-2, SIFT and PROVEAN (Protein Variation Effect Analyzer). According to pathogenicity prediction programs, it was predicted that the p.Tyr245del mutation has deleterious effect on the function of the PNPLA1 protein. (Table II) Family 3: Two affected sisters from a consanguineous family (Family III), born as collodion babies. One of the sisters (II:3) with similar findings to other sister died at eight months of age. The other sister (II:2) had diffuse erythema and white gray scales on her whole body. She had hyperkeratotic plaques on the knees, elbows and back of the neck. Thick dystrophic nails and brown teeth were observed. She had squamous pityriasiform appearance on the scalp.
The patients in the family were found to have novel c.335C>A mutation in PNPLA1 gene ( Figure 2C ). This mutation is located in the patatin domain which replaced a serine residue with a tyrosine at amino acid position 112 (p.Ser112Tyr). The exchange of hydroxyl side group of serine with aromatic side group of tyrosine may disrupt protein folding and affect catalytic patatin domain activity (Fig.  3c ). p.Ser112Tyr was also predicted to have deleterious functional effects in PNPLA1 protein (Table II) .
Discussion
This report and previous studies revealed that PNPLA1 mutations lead to various ARCI symptoms including collodion baby phenotype, generalized mild to severe scales with flexures, mild to moderate erythema, pruritus and palmoplantar keratoderma. We have not defined any unique ARCI symptom specific for PNPLA1 mutations. Clinical findings of our ARCI patients were commonly similar to previously reported symptoms. 25 Generally, the symptoms of ARCI patients with PNPLA1 mutations are relatively milder than the other forms of ARCI especially caused by TGM1 and ABCA12 mutations. 25 ARCI causing genes play important roles in differentiation of epidermal keratinocytes and/or formation of epidermal lipid barrier. Previously, ARCI causing genes CERS3, ALOX12B, CYP4F22 and ALOXE3 were reported to play role in ceramide metabolism during epidermal lipid barrier formation. 28, 29 Recently, PNPLA1 protein was reported to play role in acylceramide synthesis by catalyzing esterification of omega-hydroxyceramide with linoleic acid in epidermal cornified envelope formation. [21] [22] [23] As PNPLA1 protein plays important role in epidermal lipid barrier formation, mutations in PNPLA1 gene lead to ARCI pathology.
p.Asp172Asn mutation that we identified in 2 ARCI patients in a Turkish consanguineous family was previously reported by Zimmer A et al. 25 and Vahidnezhad H et al. 30 in Kazakh, Azeri and Lurish patients. This mutation is located at the catalytic site of PNPLA1 as Ser53 and Asp172 form catalytic dyad of patatin domain. Zimmer A et al. 25 had also reported homozygous p.Ser53Leu mutation that is located at the position of Serine 53 of catalytic dyad in patatin domain. The pathogenic mutations located at catalytic site of the protein appears frequently in ARCI patients from different ethnic background.
p.Ser112Tyr mutation which is also located at patatin domain of the protein is the novel mutation reported first time in this report. Two Turkish ARCI patients had homozygous p.Ser112Tyr mutation in a consanguineous family and this mutation probably impairs functionality of PNPLA1 and leads to ARCI pathology. In addition, we report a novel deletion mutation p.Tyr245del which leads to deletion of a tyrosine amino acid at position 245. Actually, the p.Tyr245del mutation is located between core patatin domain and proline rich domain of PNPLA1 gene. Recently, it was suggested that in addition to core patatin domain PNPLA1 protein may have a functional extended patatin domain involving N terminal residues 1-288. 25 Consistently, the p.Tyr245del mutation is exactly located at the extended patatin domain of the protein. Clinical findings of our ARCI patients reveal that the p.Tyr245del mutation in the extended patatin domain may be relevant to PNPLA1 function.
To date, twenty-six mutations in PNPLA1 gene were identified in ARCI patients from a cohort of families from various ethnic background including African-Czech, German, Swedish, Algeria, French, Pakistani Kazakh, Spanish, Morocco, Persian, Lurish, Kurdish, Arab and Azeri. 17, [24] [25] [26] [27] 30 In this study, we report novel PNPLA1 mutations identified for the first time in Turkish ARCI patients. All PNPLA1 mutations identified in ARCI patients were summarized in Table II . Nearly all reported PNPLA1 mutations including our results are localized in the core patatin domain or extended patatin domain (Fig. 4) . The other mutations located outside of patatin domain lead to early stop codon and form truncated protein which cause either loss of PNPLA1 functionality or change intracellular localization of protein. So, extended patatin domain is a disease causing mutation hot spot in the PNPLA1 gene and this domain is essential for functionality of the gene. Moreover, since almost all reported gene variations reside in the patatin domain, it draws almost all attention to functional sequence and its effect on the dysfunction of the epidermal keratinocytes.
It was assumed that the frequency of PNPLA1 mutations among ARCI patients is approximately 3%. 25 ARCI is a very rare genetic disease and in this case differential analysis has high diagnostic value. The increase in frequency and spectrum of PNPLA1 mutations show the necessity of PNPLA1 mutation analysis in ARCI patients especially in newborns with ichthyosis.
